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A B S T R A C T
The lateral tuberal nucleus (LTN) is a hypothalamic region that has been identified with
certainty only in humans and primates. It is composed of three small round globular units
which protrude the basal surface of the brain along the optic tract. The function of the LTN is
unknown. Recently, a tiny, parvalbumin-positive (PV1) nucleus was detected in the lateral
hypothalamus of rodents. Like the human LTN, the rodent PV1-nucleus is subdivided into
three units and lies along the optic tract. To ascertain whether the human LTN and the
rodent PV1-nucleus could be considered as homologous structures not only based on their
topographic location but also because of their neurochemical characteristics, we subjected
tissue samples from humans, rats andmice to immunohistochemical analysis for a panel of
neural markers. The human LTN was intensely immunoreactive for somatostatin and FF1,
but only weakly so or not at all for parvalbumin, calbindin and calretinin. The rodent PV1-
nucleus was intensely immunoreactive for parvalbumin but was not immunoreactive for
either somatostatin, a surrogate for human FF1, calbindin or calretinin. Hence, using these
neural markers, it was not possible to demonstrate a neurochemical homology between the
human LTN and the rodent PV1-nucleus.
1. Introduction
The lateral tuberal nucleus (LTN) has not yet been assigned a
clear function in primates. It is composed of three subnuclei,
which lie along the optic tract and often bulge from the lower
surface of the hypothalamus. In humans the LTN is immu-
noreactive for somatostatin, orexin A and hFF1 and undergoes
marked changes in patients suffering from either Hunting-
ton's (Hofman, 1997; Timmers et al., 1996), Pick's (Braak and
Braak, 1998) or the argyrophilic grain disease (Schultz et al.,
1998).
It is a paradigm of neuroscience that the functional analy-
sis of human brain areas is promoted and facilitated if
homologous structures are known to exist in lower mam-
mals. But in the case of the LTN, only primates appear to
possess a similar structure (Fujii, 1982; Narkiewicy et al.,
1994; Goncharuk et al., 2004). The occurrence of an LTN in
rodents is controversial. Recently, however, a tiny, parvalbu-
min-positive (PV1) nucleus has been identified in the lateral
hypothalamus of rodents. It is subdivided into three portions,
lies along the optic tract and bulges from the basal surface of
the hypothalamus (Celio, 1990; Celio and Saper, 1999, not
published results). From its topography and organization, it
is believed to be a homologue of the human LTN. This
contention would be supported if the rodent and human
counterparts were found to have similar neurochemical
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compositions. In the present study, we compare the distri-
bution of the calcium-binding proteins, neuromodulators
and neurotransmitters in the human LTN and the rodent
PV1-nucleus, with a view to identifying common chemical
markers.
2. Results
The human lateral tuberal nucleus (LTN) is located within the
most lateral aspect of the hypothalamus. It consists of three
discrete spherical entities, which are aligned along the optic
tract and protrude from the basal surface of the hypothalamus
(Figs. 1A, B). The LTN is subject to variations between
individuals. Indeed, the protuberances are not recognizable
in all brains.
In brain sections stained with Nissl's reagent, each com-
ponent of the LTN measures approximately 1.5 mm in dia-
meter, although the middle one tends to be slightly smaller
than the other two (Fig. 2A). The LTN is bordered laterally by
the optic tract, dorsolaterally by the internal capsule, medially
by the descending fornix, mediocaudally by the mamil-
lary body and ventrally by the pia mater (Kremer, 1992).
Staining with Cresyl violet–Luxol fast blue reveals the
presence of medium-sized, multipolar neurons (Fig. 2B)
(Braak and Braak, 1992). A distinct compartmentalization of
centrally and peripherally located neurons is apparent. But
within each of three regions, the cells are distributed
homogeneously (Le Gros Clark et al., 1938). The subnuclei
are traversed by relatively few myelinated fibres (Fig. 2B).
Each unit of the LTN is encapsulated by a loose fibrous
network, which is surrounded by the large cells of the
tuberomamillary nucleus.
The immunohistochemical analysis for various markers
(Table 2) reveals no correspondence between the chemoarch-
itectonic of the human LTN and the rodent PV1-nucleus. In
human brain sections treated with antibodies against
parvalbumin (Figs. 3A, B), the LTN is barely distinguishable
from the surrounding tissue. And it is immunoreactive for
neither calbindin (Figs. 3C, D) nor calretinin (Figs. 3E, F).
However, it is intensely labelled with antibodies against
Fig. 1 – Macroscopic views of the basal hypothalamus in a
human brain. (A) The slender point to the three
protuberances of the LTN, which lie between the corpora
mamillaria (CM), the tractus opticus (TO) and the pituitary
stalk (thick arrow: infundibulum). (B) Higher-magnification
view of panel A turned 90° counterclockwise, revealing
the bulging nature of the three LTN units (arrows).
Magnification: ×5.
Fig. 2 – Light micrographs of the human LTN stained with
Cresyl violet–Luxol fast blue. (A) Low-magnification view of
the LTN in which two of the three globose units are indicated
(arrows). Each subnucleus is encapsulated by a fibrous
network (×), which is surrounded by the large cells of the
tuberomamillary nucleus. F: Fornix; TO: Tractus opticus.
Magnification: ×40. (B) Higher-magnification view of panel A
revealing the presence of nerve-fibre boutons (arrows) and
cell bodies of similar diameter. Magnification: ×400.
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somatostatin (Figs. 4A, B) and the neuropeptide FF receptor
FF1 (Figs. 4C, D). In highly magnified images, fibres (probably
axons) are stained with all markers. Along their trajectory
some positively stained varicosities can be discerned with
some markers.
In mice and rats, brain sections treated with antibodies
against parvalbumin disclose the presence of labelled neu-
rones and axons within the PV1-nucleus (Figs. 5A and B). With
all other antibodies used in this study, the PV1-nucleus does
not manifest immunoreactivities, and it can be distinguished
Fig. 3 – Lightmicrographs of the humans LTN after treatmentwith antibodies against parvalbumin (A, B), calbindinD-28k (C, D)
and calretinin (E, F). (A) Low magnification view revealing weak immunoreactivity for parvalbumin within the LTN (arrows
delimit the boundaries of two subunits). Magnification: ×40. (B) Higher magnification view of panel A in which exceptionally a
rare PV-immunoreactive cells is depicted (arrow). Magnification: ×400. (C) Low magnification view of the LTN revealing the
selective absence of immunoreactivity for calbindin D-28k in the three round subnuclei (arrows). F: Fornix. Magnification: ×40.
(D) Higher-magnification view of panel C revealing the presence of a few intensely labelledmultipolar cells. The course followed
by both axons and dendrites (arrow) can be followed over relatively long distance by virtue of their immunoreactivity.
Magnification: ×400. (E) Low-magnification view of the LTN (arrows) revealing the selective absence of immunoreactivity for
calretinin (arrows). F: Fornix. Magnification: ×40. (F) Higher-magnification view of panel E revealing nomore than a background
immunostaining of the cell bodies. However, some of the traversing fibres are labelled (arrow). Magnification: ×400.
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from the surrounding tissue as negative image (data not
shown).
3. Discussion
In the present study, we wished to ascertain whether the
human LTN and the rodent PV1-nucleus could be considered
as homologues based on their neurochemical characteristics.
To this end, the structures were subjected to an immunohis-
tochemical analysis for a panel of reference neural markers.
Somatostatin, and FF1 are recognized markers if the human
LTN (Timmers et al., 1996; Goncharuk et al., 2004), whereas the
calcium-binding protein parvalbumin is the typical marker of
the rodent PV1-nucleus (hence its name) (Celio, 1990).
Specimens were subjected to an immunohistochemical
analysis not only for these markers but also for two other
calcium-binding proteins, namely calretinin and calbindin,
which also occur in the hypothalamus.
The human LTN and the rodent PV1-nucleus did not stain
alike this panel of markers. Nevertheless, subtle similarities
could be discerned. As anticipated, the human LTN mani-
fested intense immunoreactivity for somatostatin and FF1
(only fibres). The rodent PV1-nucleus did not stain for these
markers. Similarly discrepant findings in phylogeny have
been reported for the corticotropin-releasing factors, the
muscarinic cholinergic receptor and GABA, each of which
are expressed in regions of the human brain but not in the
rodent (Pelletier et al., 1983; Millan et al., 1986; De Souza et al.,
1985; Cortes et al., 1986; Trottier et al., 2002; Sakaue et al., 1988;
Tappaz et al., 1977). Neither the human LTN nor the rodent
PV1-nucleus manifested immunoreactivity for either calbin-
din or calretinin. But in each species, the surrounding tissue
was labeled. The nuclei thereby appeared in negative relief.
And in rodents, the same negative imaging of the PV1-nucleus
was observed using a surrogate antibody for human FF1 (see
Table 2).
Although the human LTN and the rodent PV1-nucleus
share a common topographic location within the hypothala-
mus, they differ for these neurochemical markers. This
paradox may be explained by phylogenetic differences in the
connections and functions of these two nuclei.With respect to
Fig. 4 – Light micrographs of the human LTN after treatment with antibodies against somatostatin 309 (A, B) and human FF1
(C, D). (A) Low-magnification view revealing strong immunoreactivity for somatostatin within the three subnuclei of the LTN
(arrow), and moderate or absent for the adjacent tissue. F: Fornix. Magnification: ×40. (B) Higher-magnification view of panel A
depicting a cell body whose surface is adumbrated by abutting immunoreactive nerve fibres (arrow). The tissue is rich in
labelled fibres and terminals. Magnification: ×400. (C) Low-magnification view of the LTN revealing intense immunoreactivity
for FF1 in the three LTN-subnuclei (arrows). F: Fornix.Magnification: ×40. (D) Higher-magnification view of panel C revealing the
abundance of immunoreactive nerve fibres and terminals. Several fibres are here seen to align the surface of a cell body (arrow).
Magnification: ×400.
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calcium-binding proteins, differences between species are
not uncommon. For instance, CA1 pyramidal neurons
express calbindin D-28k in the rat, but not in either the
human or the rabbit. Similarly, many thalamic nuclei express
calbindin D-28k and parvalbumin in monkeys, but not in rats
(Baimbridge et al., 1992).
Likewise, a quantitative comparison of the basal ganglia in
the rats, monkeys and humans has revealed marked anato-
mical and neurochemical differences between these species
(Hardman et al., 2002).
Although the function of the LTN is unknown, several
hypotheses have been proposed based on its neurochemical
composition in humans. The presence of somatostatin and of
the neuropeptide FF receptor FF1 let to speculations that it
might be involved in the regulation of food intake and in the
homeostasis of the neuroendocrine system (Timmers et al.,
1996; Goncharuk et al., 2004; Dockray, 2004; Nicklous and
Simansky, 2003).
In patient suffering from Huntington's disease, the LTN
incurs a substantial loss of cells (Kremer et al., 1991). In
individuals with either Parkinson's or Alzheimer's disease, the
number of cells does not change, but their characteristics do:
they undergo cytoskeletal alterations and manifest cytoplas-
matic inclusions such as Levy bodies (Hofman, 1997; Braak
and Braak, 1998; Kremer, 1992; Kremer et al., 1990; Kremer and
Bots, 1993). The fact that patients with neurodegenerative
disease often suffer from cachexia and sleep disorders during
the later stages of their disease (Kremer, 1992; Braak and
Braak, 1992; Morton et al., 2005), supports the contention that
the human LTN may be involved in the regulation of food
intake and of the sleep–wake cycle.
Notwithstanding the topographic and morphologic analo-
giesbetween thehumanLTNand the rodentPV1-nucleus, these
structures do not express the same panel of neurochemical
markers. Further experiments using more sophisticated tech-
niques like proteomics andgene-arraysmust nowbe conducted
to establish whether these regions can be considered as
homologues in a more subtle neurochemical respect.
4. Experimental procedures
4.1. Human brain material and tissue treatment
Ten human brains, which had been fixed in 10% buffered
formalin, were used for this study. The age and gender of the
donors, as well as the cause of their death, are summarized in
Table 1.
For cryoprotection, a single tissue block embracing the
entire hypothalamus was removed and immersed in 0.1 M
Tris-buffered saline (TBS, pH 7.3) containing 18% sucrose and
0.02 M sodium azide. When the tissue had become fully
impregnate with sucrose, it was frozen and cut into 40-μm-
thick slices on a Frigomobile (Reichert-Jung, Model 1206). The
frozen tissue sections were maintained in 0.1 M TBS contain-
ing 0.01 M sodium azide.
4.2. Rat brain material and tissue treatment
The brains of 8 male rats (300 g) and mice (50 g) were used
for this study. The animal were anesthetized with Eutha 77
Fig. 5 – Light micrographs of the rat PV-nucleus after
treatment with antibodies against parvalbumin (A, B) and
calretinin (C,D). (A) Low-magnification view revealing intense
immunoreactivity for parvalbumin within the PV1 nucleus
(circled; lateral borders indicated by arrows). LGP: lateral
globus pallidus; IC: internal capsule, ZI: zona incerta, TO:
tractus opticus. Magnification: ×40. (B) Higher-magnification
view of panel A depicting the PV-nucleus in more detail.
TO: tractus opticus. Magnification: ×400.
Table 1 – Human brain material used in this study
Case
number
Age
(years)
Gender Cause of death
223.SN.99 78 Female Myocardial infarction
171 SN 98 82 Male Lung embolism, adenocarcinoma
of the colon
249.SN.99 55 Male Myocardial infarction
20.SN.00 78 Male Dissection of aorta
219.SN.99 75 Male Prostate cancer with metastases
196.SN.99 83 Male Myocardial infarction
SN99–163 47 Male Heart disease and renal
insufficiency
244.SN.99 69 Female Lung embolism
29 SN/99 83 Female Heart disease
252.SN.99 89 Female Ruptured aneurysm of the aorta
The hypothalamus was removed from the brains of these 4 female
and 6 male cadavers, which were undergoing routine autopsies.
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and then with 4% paraformaldehyde (in 0.1 mM phosphate
buffer saline, pH 7.3) for 10 min.
The brains were excised and immersed in 0.1 M TBS
containing 18% sucrose and 0.02 M sodium azide. Thereafter,
the tissue was frozen, sectioned and stored as described above
for human material.
4.3. Immunohistochemistry
Sections of human and rodent brains were treated in parallel
according to the following protocol:
1) Pretreatment with a methanolic solution of hydrogen
peroxide (50:1) for 20 min at ambient temperature to
block the endogenous peroxidase activity;
2) rinsing in 0.1 M TBS (pH 7.3);
3) steam–pressure pretreatment with 10 mM citric buffer
for 4 min, followed by rinsing in tap water for 5 min;
4) one 5-min wash in 0.1 M TBS;
5) incubation with primary antibodies (see Table 2), which
was diluted in 0.1 M TBS (pH 7.3) containing 1% Triton X-
100 and 10% bovine serum albumin, for 3 days at 4 °C;
6) three 5-min rinses in 0.1 M TBS;
7) incubation with biotinylated polyclonal goat anti-rabbit
IgG for 2 hours at 37 °C in a humidified atmosphere;
8) three 5-min rinses in 0.1 M TBS;
9) incubation with the avidin–peroxidase complex for 2 h
at 37 °C in a humidified atmosphere;
10) three 5-min rinses in 0.1 M TBS;
11) incubation in DAB (3,3-diaminobenzidine) containing
hydrogen peroxide for 10 min;
12) two 5-min rinses in 0.1 M TBS;
13) dehydration in 70% (5 min), 94% (5 min) and 100%
ethanol (10 min, with a change of medium halfway),
clearance in xylene (10 min, with a change of medium
halfway) and mounting in Entellan.
4.4. Antibodies
The antibodies used in this study, as well as their sources, are
described in Table 2.
4.5. Image processing
Macroscopic images of the human brain were acquired
digitally using a Nikon SMZ1000 instrument equipped with a
Nikon digital camera DXM1200. Microscopic images of the
slices were taken with the same Nikon camera using a Nikon
Eclipse E400 microscope.
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